Analyzes changes in antibody levels after CD19 CAR T-cell therapy in lymphoma patients, suggesting revaccination may not be needed.
MeV, MuV, RuV, VZV, and tetanus toxoid IgG remained stable following CD19 CAR T-cell therapy, while pneumococcal and Hib IgG titers showed marginal quantitative declines, without any fourfold reductions. Overall, humoral immunity at Day 100 following CD19 CAR T-cell therapy remained largely preserved. These seroprevalence findings suggest that routine revaccination may not be required in our patient cohort and highlight the importance of patient monitoring to inform revaccination decisions.
No takes yet. Share an insight, caveat, or question.
Foy-Stones et al. (2026) studied this question.